U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Carcinoid Tumor

MedGen UID:
1649766
•Concept ID:
C4744858
•
Neoplastic Process

Definition

A carcinoid tumor that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Professional guidelines

PubMed

Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management.
Jin C, Sharma AN, Thevakumar B, Majid M, Al Chalaby S, Takahashi N, Tanious A, Arockiam AD, Beri N, Amsterdam EA
Cardiology 2021;146(1):65-73. Epub 2020 Oct 16 doi: 10.1159/000507847. PMID: 33070143
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H
Int J Mol Sci 2019 Jun 22;20(12) doi: 10.3390/ijms20123049. PMID: 31234481Free PMC Article
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Ito T, Lee L, Jensen RT
Expert Opin Pharmacother 2016 Nov;17(16):2191-2205. Epub 2016 Sep 23 doi: 10.1080/14656566.2016.1236916. PMID: 27635672Free PMC Article

Recent clinical studies

Diagnosis

Carcinoid--a comprehensive review.
Schnirer II, Yao JC, Ajani JA
Acta Oncol 2003;42(7):672-92. doi: 10.1080/02841860310010547. PMID: 14690153
Magnetic resonance imaging of an ileal carcinoid tumor. Correlation with CT and US.
Maccioni F, Almberger M, Bruni A, Parlanti S, Marini M
Clin Imaging 2003 Nov-Dec;27(6):403-7. doi: 10.1016/s0899-7071(03)00004-4. PMID: 14585569

Therapy

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA
J Clin Oncol 2008 Mar 10;26(8):1316-23. doi: 10.1200/JCO.2007.13.6374. PMID: 18323556

Prognosis

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA
J Clin Oncol 2008 Mar 10;26(8):1316-23. doi: 10.1200/JCO.2007.13.6374. PMID: 18323556
Carcinoid--a comprehensive review.
Schnirer II, Yao JC, Ajani JA
Acta Oncol 2003;42(7):672-92. doi: 10.1080/02841860310010547. PMID: 14690153

Clinical prediction guides

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA
J Clin Oncol 2008 Mar 10;26(8):1316-23. doi: 10.1200/JCO.2007.13.6374. PMID: 18323556
Carcinoid--a comprehensive review.
Schnirer II, Yao JC, Ajani JA
Acta Oncol 2003;42(7):672-92. doi: 10.1080/02841860310010547. PMID: 14690153

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...